A cancer detection technology developed at Broad powers a test for MRD #science @broadinstitute
A cancer detection technology developed at Broad powers a test for MRD #science  @broadinstitute
Uploaded November 2026 | Updated November 2026, 5 days ago
A cancer detection technology developed at the Broad Institute now powers a next-generation test for molecular residual disease (MRD) launched this week by Abbott. The personalized Oncodetect® test looks for MRD — traces of cancer DNA that may remain in the body during and after treatment. It’s the result of years of collaborative work from Broad and Abbott scientists and partners from research hospitals.
A cancer detection technology developed at Broad powers a test for MRD #sciencegVasc Saliva Kit TutorialMPG Primer: Noncoding Variants in Genetic Diagnoses (2026)MPG Primer: ClinGen, ClinVar and other Clinical Genomic Resources (2025)CLEAR 2026: Keynote, Proxy Variables for Causal Effect Estimation with Hidden ConfoundingGlobal views of developmentMPG Primer: Career Panel DiscussionEWSC Talk: The Virtual Biotech: A Multi-Agent AI Framework for Therapeutic Discovery and DevelopmentMPG Primer: A primer on genomic sequence-to-function (S2F) modeling (2026)MIA: Abhinav Adduri, Multi-Scale Modeling of Cellular Responses to Perturbation with STATEObesity ML Competition: Lecture 3, Part C - Crunches OverviewDecoupling & Dimensionality: Two Frameworks for Interpretable Multi-Modal Representation Learning
Broad Institute |

A cancer detection technology developed at Broad powers a test for MRD #science

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER